Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OBJECTIVES: Primary * To determine the efficacy, in terms of overall response, and safety of paclitaxel and carboplatin in combination with intermittent gefitinib in patients with advanced nonsquamous non-small cell lung cancer. Secondary * Determine the disease-control rate in patients treated with this regimen. * Determine the quality of life of patients treated with this regimen. * Determine the progression-free and overall survival of patients treated with this regimen. OUTLINE: Patients receive paclitaxel IV on day 1, carboplatin IV on day 2, and oral gefitinib once daily on days 8-17. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses, patients with complete response or partial response may continue maintenance therapy comprising oral gefitinib once daily in the absence of disease progression or unacceptable toxicity. Patients complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline, during study treatment, and after completion of study treatment for quality-of-life study. After completion of study treatment, patients are followed every 2 months for 2 years and then every 4 months thereafter.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
